These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 20334788)
21. [Pemetrexed monotherapy in previously treated patients with advanced non small cell lung cancer; differences by histology. Our experience]. Pistillucci G; Sciacca V; Ciorra A; Di Palma T; Calabretta F; Lugini A; Rossi R; D'Aprile M; Veltri E Recenti Prog Med; 2012 Feb; 103(2):62-5. PubMed ID: 22430749 [TBL] [Abstract][Full Text] [Related]
22. New avenues for second-line treatment of metastatic non-small-cell lung cancer. Gridelli C; Maione P; Rossi A; Falanga M; Bareschino M; Schettino C; Colantuoni G; Guerriero C; Nicolella D; Rossi E; Ferrara ML; Palazzolo G Expert Rev Anticancer Ther; 2009 Jan; 9(1):115-24. PubMed ID: 19105711 [TBL] [Abstract][Full Text] [Related]
23. Activity of pemetrexed on brain metastases from non-small cell lung cancer: what is the mechanism? Dogan M; Yalcin B; Utkan G; Urun Y; Ozal G Lung Cancer; 2009 Dec; 66(3):399. PubMed ID: 19783320 [No Abstract] [Full Text] [Related]
24. [Analysis of therapeutic efficacy in 49 patients with advanced non-small cell cancer treated with gefitinib]. Zhang PL; Chen L Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):635-6. PubMed ID: 18210890 [No Abstract] [Full Text] [Related]
25. [Second-line treatment of advanced non-small-cell lung cancer: role of pemetrexed]. Pérol M Rev Pneumol Clin; 2005 Sep; 61(4 Pt 2):4S14-7. PubMed ID: 16273004 [No Abstract] [Full Text] [Related]
26. [Report from a small registry-permetrexed, tarceva and yondelis]. Pochop L; Hejduk K Klin Onkol; 2013; 26(1):53-4. PubMed ID: 23607142 [No Abstract] [Full Text] [Related]
27. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin. Tiseo M; Giovannetti E; Tibaldi C; Camerini A; Di Costanzo F; Barbieri F; Burgers JA; Vincent A; Peters GJ; Smit EF; Ardizzoni A Lung Cancer; 2012 Oct; 78(1):92-9. PubMed ID: 22889494 [TBL] [Abstract][Full Text] [Related]
28. Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression. Igawa S; Ryuge S; Wada M; Otani S; Maki S; Takakura A; Katono K; Sasaki J; Sato Y; Masuda N Chemotherapy; 2012; 58(4):313-20. PubMed ID: 23147191 [TBL] [Abstract][Full Text] [Related]
29. Overview of MTA in the treatment of non-small cell lung cancer. Postmus PE; Green MR Semin Oncol; 1999 Feb; 26(1 Suppl 4):31-6. PubMed ID: 10201519 [TBL] [Abstract][Full Text] [Related]
30. Implications of the Iressa Survival Evaluation in Lung Cancer trial and the future of gefitinib. Belani CP; Ramalingam S Clin Lung Cancer; 2005 Jan; 6(4):203-4. PubMed ID: 15694010 [No Abstract] [Full Text] [Related]
32. Pemetrexed: current development and future directions in thoracic cancers. Manegold C Suppl Tumori; 2002; 1(4):S11-2. PubMed ID: 12415805 [No Abstract] [Full Text] [Related]
33. Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma. Garfield DH J Clin Oncol; 2005 Oct; 23(30):7738-40. PubMed ID: 16234533 [No Abstract] [Full Text] [Related]
34. Using EGFR status to personalize treatment: lung cancer researchers reach a milestone. Friedrich MJ J Natl Cancer Inst; 2009 Aug; 101(15):1039-41. PubMed ID: 19638503 [No Abstract] [Full Text] [Related]
35. Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer. Carlson JJ; Wong WB; Veenstra DL; Reyes C J Med Econ; 2011; 14(2):159-66. PubMed ID: 21288059 [TBL] [Abstract][Full Text] [Related]